Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2021

View Archived Issues

Regenxbio initiates phase I/II study of RGX-121 gene therapy

Tessa Therapeutics enrolling participants in phase II CHARIOT study of CD30.CAR-T therapy

Celon successfully completes phase Ia study of CPL-116

BenevolentAI begins first-in-human trial of BEN-2293 for atopic dermatitis

New cancer anorexia therapeutic target identified

Wistar Institute patents new antibacterials against Pseudomonas

Sinocelltech discloses new anti-VEGF antibodies

Amicus reports topline phase III data on AT-GAA for late-onset Pompe disease

FDA clears IND for trial of LYS-GM101 in GM1 gangliosidosis

Bristol Myers Squibb synthesizes IRAK-4 inhibitors

Harbin Boyicheng Biotechnology discloses new HER2-targeting nanobodies

Last patient completes final visit for NORSE THREE safety study of ONS-5010

Capella BioScience discovers anti-PD-L1 antibodies

Researchers describe activity of BNT-162b2 against SARS-CoV-2 mutations

Specialization improves synthetic circuits

Preclinical findings support the use of HMI-202 for treating MLD

InflaRx presents data from phase IIb SHINE study of vilobelimab

Data on HMI-203 from animal studies support its further development for treating MPS II

European Commission approves Ogluo to treat severe hypoglycemia

New phase I/II trial investigates JSP-191 in sickle cell disease

FDA approves Evkeeza for homozygous familial hypercholesterolemia

Tukysa approved in E.U. for HER2-positive locally advanced or metastatic breast cancer

AC Immune reports interim data from phase Ib/II study of anti-pTau vaccine candidate ACI-35.030

Spanish AEMPS approves CAR-T ARI-0001 for ALL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...